All In Biotech

Investigational drug · Phase 3

ABP-671

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Kidney Disease, Gout.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

8

Any phase or sponsor naming "ABP-671"

First trial start

2023

Aug 11, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ABP-671", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Chronic Kidney Disease
  • Gout

Approved drugs for the same conditions: Gout · Chronic kidney disease · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "ABP-671" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Chronic Kidney Disease

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

  • ElecoglipronPhase 39 trials

    AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight

  • ZenagamtidePhase 39 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • lorundrostatPhase 35 trials

    Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease

  • VicadrostatBI 690517Phase 35 trials

    Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension

  • HRS-1780Phase 33 trials

    Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.